Dendreon (NASDAQ:DNDN) Slashes 600 Jobs to Lower Costs – DNDN, BPAX, NLNK, PPHM
The Seattle-based Dendreon Corporation (NASDAQ:DNDN), manufacturer of the prostate cancer medicine Provenge, reported that it would remove over 600 jobs and lower costs by $150 million during the...
View ArticleDendreon’s (NASDAQ:DNDN) Provenge Sales Hikes 27% in the Q3; Stock Lifts –...
Dendreon Corporation (NASDAQ:DNDN) reported on Friday that revenue from its prostate cancer therapy Provenge moved up 27% in the Q3. Shares of the company hiked 16% after the report. Dendreon’s...
View ArticleDendreon (NASDAQ:DNDN) Swings to Loss in Fiscal Q4; Stock Tumbles – DNDN,...
Dendreon Corporation (NASDAQ:DNDN) on Monday announced a quarterly loss evaluated against a profit in previous year as revenue tumbled and restructuring expenses weighed on the biotechnology...
View ArticleUS Stock Market Movers Roundup: Merck, Bristol Myers Squibb, NewLink...
Merck & Co, Inc’s (NYSE:MRK) stock hiked over 3.5% after its experimental medicine shrank tumors in a promising number of skin-cancer patients in a clinical inquiry, the most recent milestone for...
View Article
